MacroGenics Inc. (NASDAQ:MGNX)’s share price rose 2.9% on Wednesday . The stock traded as high as $29.82 and last traded at $29.80, with a volume of 52,506 shares traded. The stock had previously closed at $28.97.

MGNX has been the topic of several research reports. BTIG Research initiated coverage on shares of MacroGenics in a research note on Thursday, April 7th. They issued a “buy” rating and a $35.00 price target on the stock. Morgan Stanley raised their price target on shares of MacroGenics from $20.00 to $21.00 in a research note on Friday, April 8th. Zacks Investment Research raised shares of MacroGenics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and set a $52.00 target price on shares of MacroGenics in a research note on Wednesday, May 4th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $47.00 target price on shares of MacroGenics in a research note on Thursday, May 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. MacroGenics has an average rating of “Buy” and a consensus price target of $40.25.

The firm’s 50 day moving average price is $26.61 and its 200 day moving average price is $21.49. The company’s market capitalization is $1.03 billion.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.21. On average, equities analysts anticipate that MacroGenics Inc. will post ($2.29) EPS for the current year.

In related news, VP Lynn Cilinski sold 5,000 shares of the stock in a transaction on Friday, May 27th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the vice president now owns 6,923 shares in the company, valued at $173,075. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC boosted its position in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock worth $8,282,000 after buying an additional 909 shares in the last quarter. Marshall Wace LLP boosted its position in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock worth $2,902,000 after buying an additional 45,422 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 20,929 shares in the last quarter. GAM Holding AG boosted its position in MacroGenics by 118.3% in the fourth quarter. GAM Holding AG now owns 63,100 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 34,200 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 1,038 shares in the last quarter.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.